JP2018530530A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018530530A5 JP2018530530A5 JP2018512125A JP2018512125A JP2018530530A5 JP 2018530530 A5 JP2018530530 A5 JP 2018530530A5 JP 2018512125 A JP2018512125 A JP 2018512125A JP 2018512125 A JP2018512125 A JP 2018512125A JP 2018530530 A5 JP2018530530 A5 JP 2018530530A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- combination according
- group
- deoxyribonucleic acid
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091026890 Coding region Proteins 0.000 claims 8
- 239000002773 nucleotide Substances 0.000 claims 5
- 125000003729 nucleotide group Chemical group 0.000 claims 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 108020004414 DNA Proteins 0.000 claims 3
- 102000053602 DNA Human genes 0.000 claims 2
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical group O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 210000000987 immune system Anatomy 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- CKTSBUTUHBMZGZ-ULQXZJNLSA-N 4-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-tritiopyrimidin-2-one Chemical compound O=C1N=C(N)C([3H])=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-ULQXZJNLSA-N 0.000 claims 1
- 102100026882 Alpha-synuclein Human genes 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims 1
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 1
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 1
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 claims 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 102000017578 LAG3 Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108020004682 Single-Stranded DNA Proteins 0.000 claims 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000000139 costimulatory effect Effects 0.000 claims 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LU92821 | 2015-09-09 | ||
| LU92821A LU92821B1 (en) | 2015-09-09 | 2015-09-09 | Combination comprising immunostimulatory oligonucleotides |
| PCT/EP2016/071314 WO2017042336A1 (en) | 2015-09-09 | 2016-09-09 | Combination comprising immunostimulatory oligonucleotides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020210230A Division JP2021059566A (ja) | 2015-09-09 | 2020-12-18 | 免疫刺激オリゴヌクレオチドを含む組合せ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018530530A JP2018530530A (ja) | 2018-10-18 |
| JP2018530530A5 true JP2018530530A5 (enExample) | 2019-09-26 |
Family
ID=54251700
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018512125A Pending JP2018530530A (ja) | 2015-09-09 | 2016-09-09 | 免疫刺激オリゴヌクレオチドを含む組合せ |
| JP2020210230A Pending JP2021059566A (ja) | 2015-09-09 | 2020-12-18 | 免疫刺激オリゴヌクレオチドを含む組合せ |
| JP2022023832A Active JP7436535B2 (ja) | 2015-09-09 | 2022-02-18 | 免疫刺激オリゴヌクレオチドを含む組合せ |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020210230A Pending JP2021059566A (ja) | 2015-09-09 | 2020-12-18 | 免疫刺激オリゴヌクレオチドを含む組合せ |
| JP2022023832A Active JP7436535B2 (ja) | 2015-09-09 | 2022-02-18 | 免疫刺激オリゴヌクレオチドを含む組合せ |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10487333B2 (enExample) |
| EP (1) | EP3347468B1 (enExample) |
| JP (3) | JP2018530530A (enExample) |
| KR (1) | KR102411799B1 (enExample) |
| CN (1) | CN108138179B (enExample) |
| AU (1) | AU2016319214B2 (enExample) |
| CA (1) | CA2997319C (enExample) |
| ES (1) | ES2905891T3 (enExample) |
| IL (1) | IL257921B (enExample) |
| LU (1) | LU92821B1 (enExample) |
| MX (1) | MX2018002665A (enExample) |
| PL (1) | PL3347468T3 (enExample) |
| PT (1) | PT3347468T (enExample) |
| RU (1) | RU2766693C2 (enExample) |
| SI (1) | SI3347468T1 (enExample) |
| WO (1) | WO2017042336A1 (enExample) |
| ZA (1) | ZA201801001B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105579582A (zh) | 2013-07-25 | 2016-05-11 | 埃克西奎雷股份有限公司 | 用于预防和治疗用途的作为免疫刺激剂的基于球形核酸的构建体 |
| AU2015349680A1 (en) | 2014-11-21 | 2017-06-08 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
| LU92821B1 (en) | 2015-09-09 | 2017-03-20 | Mologen Ag | Combination comprising immunostimulatory oligonucleotides |
| GB2542425A (en) | 2015-09-21 | 2017-03-22 | Mologen Ag | Means for the treatment of HIV |
| WO2017058859A1 (en) | 2015-09-29 | 2017-04-06 | Celgene Corporation | Pd-1 binding proteins and methods of use thereof |
| US12202856B2 (en) | 2016-05-19 | 2025-01-21 | The General Hospital Corporation | Tethered interleukin-2 to its receptor IL-2RBETA, a platform to enhance natural killer and regulatory T cell activity |
| WO2018039629A2 (en) | 2016-08-25 | 2018-03-01 | Northwestern University | Micellar spherical nucleic acids from thermoresponsive, traceless templates |
| JP2019534859A (ja) | 2016-09-19 | 2019-12-05 | セルジーン コーポレイション | Ｐｄ−１結合タンパク質を使用して白斑を治療する方法 |
| EP3515944A4 (en) | 2016-09-19 | 2020-05-06 | Celgene Corporation | METHODS OF TREATING IMMUNE DISORDERS WITH PD-1 BINDING PROTEINS |
| EP3392345A1 (en) | 2017-04-22 | 2018-10-24 | Mologen AG | Biomarker for small cell lung cancer therapy |
| WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
| CN111278510A (zh) * | 2017-08-31 | 2020-06-12 | 莫洛根股份公司 | 用于调节肿瘤微环境的tlr-9激动剂 |
| TW202011959A (zh) | 2018-04-14 | 2020-04-01 | 美商戴納瓦克斯技術公司 | 用於治療癌症之包括CpG-C 型寡核苷酸及組蛋白去乙醯酶抑制劑之組合 |
| EP3947640A4 (en) | 2019-04-02 | 2022-12-14 | The Brigham & Women's Hospital, Inc. | PROCEDURE FOR DETERMINING THE PROGRESSION OF PRIMARY MELANOMA |
| CN112007149A (zh) * | 2019-05-29 | 2020-12-01 | 思格(苏州)生物科技有限公司 | 一种新型复合免疫佐剂及其应用 |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB191115253A (en) | 1911-06-30 | 1912-06-20 | Adolph Schneider | Improvements in Bottle-filling Machines. |
| US2382696A (en) | 1939-04-01 | 1945-08-14 | Milleville Marie Joseph Mau De | Method and apparatus for filling containers |
| GB684057A (en) | 1949-11-30 | 1952-12-10 | Stockholms Bryggerier Ab | Machine of the rotatory table type for the treatment of bottles and the like containers |
| US2699718A (en) | 1952-04-10 | 1955-01-18 | Francis X Wright | Filling apparatus with beverage preparation mechanism |
| FR1418965A (fr) | 1964-10-14 | 1965-11-26 | Chelle Ets | Tireuse de liquides à double utilisation |
| AU554222B2 (en) | 1981-10-13 | 1986-08-14 | Toyo Garasu K.K. | Inspecting glass containers |
| ES2099718T3 (es) | 1990-07-02 | 1997-06-01 | Hoechst Ag | Analogos de oligonucleotidos con uniones internucleotidicas de 3'-3' o 5'-5' terminales. |
| EP1602725A3 (en) | 1993-09-02 | 2006-03-29 | Sirna Therpeutics, Inc. | Abasic-nucleotide containing enzymatic nucleic acid |
| WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US20030050263A1 (en) | 1994-07-15 | 2003-03-13 | The University Of Iowa Research Foundation | Methods and products for treating HIV infection |
| FR2732971B1 (fr) | 1995-04-13 | 1997-07-04 | Genset Sa | Oligonucleotide sens inhibiteur de virus herpes simplex (hsv) a structure en haltere |
| US5856462A (en) | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
| CZ120699A3 (cs) | 1996-10-16 | 1999-09-15 | Icn Pharmaceuticals, Inc. | Monocyklická L-nukleosidová analoga a jejich využití |
| DE19648625A1 (de) | 1996-11-13 | 1998-05-14 | Soft Gene Gmbh | Mikroprojektil für das Einbringen von Substanzen in Zellen durch ballistischen Transfer |
| EP0855184A1 (en) | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination |
| US6251666B1 (en) | 1997-03-31 | 2001-06-26 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid catalysts comprising L-nucleotide analogs |
| US6589940B1 (en) | 1997-06-06 | 2003-07-08 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
| US6192481B1 (en) | 1998-08-18 | 2001-02-20 | International Business Machines Corporation | Structure and method for power sequencing of disk drives in a computer system |
| CA2371994C (en) | 1999-02-26 | 2010-09-28 | Guido Grandi | Enhancement of bactericidal activity of neisseria antigens with oligonucleotides containing cg motifs |
| US6977245B2 (en) | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
| US6737066B1 (en) | 1999-05-06 | 2004-05-18 | The Immune Response Corporation | HIV immunogenic compositions and methods |
| ATE306938T1 (de) | 1999-06-29 | 2005-11-15 | Glaxosmithkline Biolog Sa | Verwendung von cpg als adjuvans für hivimpstoff |
| DE19935756A1 (de) * | 1999-07-27 | 2001-02-08 | Mologen Forschungs Entwicklung | Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation |
| AU1656601A (en) | 1999-11-12 | 2001-06-12 | Isis Pharmaceuticals, Inc. | Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages |
| DE60132471T2 (de) | 2000-09-26 | 2009-01-15 | Idera Pharmaceuticals, Inc., Cambridge | Modulation der immunostimulatorischen aktivität von immunostimulierenden oligonukleotidanaloga durch positionelle chemische veränderungen |
| DE10290185D2 (de) | 2001-01-31 | 2004-04-15 | Mologen Forschungs Entwicklung | Tumorvakzine |
| CA2452458A1 (en) | 2001-07-03 | 2003-01-16 | Isis Pharmaceuticals, Inc. | Nuclease resistant chimeric oligonucleotides |
| AU2002349278A1 (en) | 2001-10-02 | 2003-04-22 | Mologen Ag | Dna-expression construct for treatment of infections with leishmaniasis |
| ES2254758T3 (es) | 2001-10-02 | 2006-06-16 | Mologen Ag | Medicamento para mejorar la respuesta inmunitaria. |
| WO2003035836A2 (en) | 2001-10-24 | 2003-05-01 | Hybridon Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
| US7276489B2 (en) | 2002-10-24 | 2007-10-02 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends |
| JP2003204793A (ja) | 2002-01-15 | 2003-07-22 | Takeda Chem Ind Ltd | ウイルス性疾患の予防または治療剤 |
| DE10211558A1 (de) | 2002-03-15 | 2003-10-09 | Noxxon Pharma Ag | Neue Formen RNAi |
| US7605138B2 (en) * | 2002-07-03 | 2009-10-20 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| WO2004041183A2 (en) | 2002-11-01 | 2004-05-21 | The Regents Of The University Of California | Methods of treating pulmonary fibrotic disorders |
| US8158768B2 (en) | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
| US7501503B2 (en) | 2002-12-31 | 2009-03-10 | Mcgill University | Compositions and methods for inhibiting RNase H activity of retroid reverse transcriptase |
| WO2004084940A1 (en) | 2003-03-26 | 2004-10-07 | Cytos Biotechnology Ag | Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use |
| ATE340264T1 (de) | 2003-06-10 | 2006-10-15 | Mologen Ag | Zirkuläres expressionskonstrukt für gentherapeutische anwendungen |
| KR101107818B1 (ko) | 2003-10-30 | 2012-01-31 | 콜레이 파마시티컬 그룹, 인코포레이티드 | 향상된 면역자극 효능을 가진 ｃ-부류 올리고뉴클레오티드유사체 |
| JP2007512845A (ja) | 2003-12-02 | 2007-05-24 | アネシバ・インコーポレイテッド | Ｎｆ−κｂオリゴヌクレオチドデコイ分子 |
| RU2354694C2 (ru) | 2003-12-30 | 2009-05-10 | Мологен Аг | Аллогенное противоопухолевое терапевтическое средство |
| CN1918293A (zh) | 2004-02-20 | 2007-02-21 | 莫洛根股份公司 | 用于对人及高等动物进行治疗性和预防性免疫刺激的取代的非编码核酸分子 |
| JP3976742B2 (ja) | 2004-02-27 | 2007-09-19 | 江守商事株式会社 | インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド |
| US20090004703A1 (en) | 2004-05-28 | 2009-01-01 | Mologen Ag | Method for the Production of Suitable Dna Constructs for Specific Inhibition of Gene Expression by Rna Interference |
| EP1765417A4 (en) | 2004-06-15 | 2009-03-25 | Idera Pharmaceuticals Inc | MULTIMERS OF OLIGONUCLEOTIDES IMMUNOSTIMULATORS |
| WO2006015560A1 (de) | 2004-08-09 | 2006-02-16 | Mologen Ag | Immunmodulierendes mittel in verbindung mit chemotherapeutischen massnahmen |
| US7879992B2 (en) | 2005-01-31 | 2011-02-01 | Isis Pharmaceuticals, Inc. | Modification of MyD88 splicing using modified oligonucleotides |
| WO2006091591A1 (en) | 2005-02-22 | 2006-08-31 | The Regents Of The University Of California | Methods of treating gastrointestinal inflammation |
| EP1899467A2 (en) | 2005-04-26 | 2008-03-19 | Coley Pharmaceutical GmbH | Modified oligoribonucleotide analogs with enhances immunostimulatory activity |
| EP2982679A1 (en) | 2005-10-12 | 2016-02-10 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response |
| EA200801045A1 (ru) | 2005-10-12 | 2008-10-30 | Кэнсер Рисерч Текнолоджи Лтд. | Способы и композиции для лечения иммунных нарушений |
| AU2006315632A1 (en) | 2005-11-11 | 2007-05-24 | Pfizer, Inc. | Combinations and methods of using an immunomodulatory oligodeoxynucleotide |
| CN102517292B (zh) | 2005-11-25 | 2014-12-24 | 佐蒂斯比利时股份有限公司 | 免疫刺激性寡核糖核苷酸 |
| CN101313067B (zh) | 2005-11-25 | 2014-04-02 | 莫洛根股份公司 | 以rna干扰特异性抑制基因表达的dna构建体 |
| AU2007211334A1 (en) | 2006-02-01 | 2007-08-09 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders |
| MX2008014380A (es) * | 2006-05-11 | 2009-03-02 | Mologen Ag | Multimero para inmunoestimulacion. |
| EP2032144A4 (en) | 2006-06-13 | 2011-05-04 | Bayhill Therapeutics Inc | METHODS AND COMPOSITIONS BASED ON NUCLEIC ACID MODULATORS OF THE IMMUNE SYSTEM FOR THE PREVENTION AND TREATMENT OF DISEASE |
| SI2068918T2 (sl) | 2006-09-26 | 2024-10-30 | Access To Advanced Health Institute | Sestavek za cepljenje, ki vsebuje sintetična pomagala |
| US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| US20080260820A1 (en) | 2007-04-19 | 2008-10-23 | Gilles Borrelly | Oral dosage formulations of protease-resistant polypeptides |
| EP2152889B1 (en) | 2007-05-29 | 2017-03-15 | Nature Technology Corporation | Vectors and methods for genetic immunization |
| NZ582822A (en) | 2007-07-27 | 2012-06-29 | Immatics Biotechnologies Gmbh | Novel immunogenic epitopes for immunotherapy |
| WO2009035554A2 (en) | 2007-09-07 | 2009-03-19 | University Of Florida Research Foundation, Inc. | Superior structure stability and selectivity of hairpin nucleic acid probes with an l-dna stem |
| RU2010112771A (ru) | 2007-10-09 | 2011-11-20 | Коули Фармасьютикал ГмбХ (DE) | Иммуностимулирующие аналоги олигонуклеотидов, содержащие модифицированные сахарные группировки |
| EP2058397A1 (de) | 2007-11-07 | 2009-05-13 | Mologen AG | Multimeres Assemblat zur Immunstimulation |
| WO2009069447A1 (ja) | 2007-11-28 | 2009-06-04 | Toray Industries, Inc. | インフルエンザワクチン用のアジュバント及びインフルエンザワクチン |
| JP5359883B2 (ja) | 2007-11-28 | 2013-12-04 | 東レ株式会社 | 肝炎の治療剤又は予防剤 |
| WO2010039137A1 (en) | 2008-10-02 | 2010-04-08 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response |
| EP2246433A1 (de) | 2009-04-30 | 2010-11-03 | Mologen AG | Concatemere zur Immunmodulation |
| CA2794558A1 (en) | 2010-03-26 | 2011-09-29 | Patricia Bourguignon | Hiv vaccine |
| GB201021867D0 (en) | 2010-12-23 | 2011-02-02 | Mologen Ag | Non-coding immunomodulatory DNA construct |
| GB201021873D0 (en) | 2010-12-23 | 2011-02-02 | Mologen Ag | DNA expression construct |
| JP5761707B2 (ja) | 2011-02-02 | 2015-08-12 | 国立研究開発法人産業技術総合研究所 | 高効率細胞融合法 |
| US20140294765A1 (en) * | 2012-06-21 | 2014-10-02 | Compugen Ltd. | Lsr antibodies, and uses thereof for treatment of cancer |
| GB2514591A (en) | 2013-05-30 | 2014-12-03 | Mologen Ag | Predictive biomarker for cancer therapy |
| GB2523187A (en) | 2014-02-18 | 2015-08-19 | Mologen Ag | Covalently closed non-coding immunomodulatory DNA construct |
| LU92821B1 (en) | 2015-09-09 | 2017-03-20 | Mologen Ag | Combination comprising immunostimulatory oligonucleotides |
| GB2542425A (en) | 2015-09-21 | 2017-03-22 | Mologen Ag | Means for the treatment of HIV |
| EP3392345A1 (en) | 2017-04-22 | 2018-10-24 | Mologen AG | Biomarker for small cell lung cancer therapy |
| CN111278510A (zh) | 2017-08-31 | 2020-06-12 | 莫洛根股份公司 | 用于调节肿瘤微环境的tlr-9激动剂 |
-
2015
- 2015-09-09 LU LU92821A patent/LU92821B1/en active IP Right Grant
-
2016
- 2016-09-09 KR KR1020187006249A patent/KR102411799B1/ko active Active
- 2016-09-09 AU AU2016319214A patent/AU2016319214B2/en active Active
- 2016-09-09 CA CA2997319A patent/CA2997319C/en active Active
- 2016-09-09 US US15/756,798 patent/US10487333B2/en active Active
- 2016-09-09 MX MX2018002665A patent/MX2018002665A/es unknown
- 2016-09-09 PL PL16767192T patent/PL3347468T3/pl unknown
- 2016-09-09 JP JP2018512125A patent/JP2018530530A/ja active Pending
- 2016-09-09 EP EP16767192.4A patent/EP3347468B1/en active Active
- 2016-09-09 PT PT167671924T patent/PT3347468T/pt unknown
- 2016-09-09 ES ES16767192T patent/ES2905891T3/es active Active
- 2016-09-09 IL IL257921A patent/IL257921B/en unknown
- 2016-09-09 RU RU2018108353A patent/RU2766693C2/ru not_active Application Discontinuation
- 2016-09-09 SI SI201631440T patent/SI3347468T1/sl unknown
- 2016-09-09 WO PCT/EP2016/071314 patent/WO2017042336A1/en not_active Ceased
- 2016-09-09 CN CN201680059686.9A patent/CN108138179B/zh active Active
-
2018
- 2018-02-14 ZA ZA2018/01001A patent/ZA201801001B/en unknown
-
2019
- 2019-06-26 US US16/450,324 patent/US10604760B2/en active Active
-
2020
- 2020-02-18 US US16/793,334 patent/US11578331B2/en active Active
- 2020-12-18 JP JP2020210230A patent/JP2021059566A/ja active Pending
-
2022
- 2022-02-18 JP JP2022023832A patent/JP7436535B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018530530A5 (enExample) | ||
| RU2018108353A (ru) | Комбинация, включающая иммуностимулирующие олигонуклеотиды | |
| JP2014509511A5 (enExample) | ||
| JP2016116520A5 (enExample) | ||
| JP2017505623A5 (enExample) | ||
| HRP20241138T1 (hr) | Oligonukleotidi za induciranje ekspresije očinskog ube3a | |
| EP4632075A3 (en) | Method for reducing immunogenicity of rna | |
| JP2018512041A5 (enExample) | ||
| JP2017523777A5 (enExample) | ||
| JP2018533954A5 (enExample) | ||
| JP2019527563A5 (enExample) | ||
| JP2015171368A5 (enExample) | ||
| JP2011509258A5 (enExample) | ||
| JP2016520310A5 (enExample) | ||
| JP2017536119A5 (enExample) | ||
| JP2012505657A5 (enExample) | ||
| JP2019506862A5 (enExample) | ||
| JP2016522674A5 (enExample) | ||
| JP2012505250A5 (enExample) | ||
| JP2014518612A5 (enExample) | ||
| JP2013535210A5 (enExample) | ||
| JP2018519835A5 (enExample) | ||
| JP2015532097A5 (enExample) | ||
| JP2015511821A5 (enExample) | ||
| JP2015128433A5 (enExample) |